Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796552 | 0.96 | KDM4E (0.57) | KDM4EPKMGPR119STSTHRB | |
| SCHEMBL9023290 | 0.93 | KDM4E (0.55) | KDM4EPKMGPR119STSTHRB | |
| SCHEMBL8444736 | 0.89 | KDM4E (0.59) | KDM4EPKMGPR119STSTHRB | |
| SCHEMBL5453826 | 0.88 | GPR119 (0.51) | KDM4EPKMGPR119THRBMAPT | |
| SCHEMBL23329642 | 0.86 | ALDH1A1 (0.59) | KDM4EPKMGPR119STSTGFBR1 | |
| SCHEMBL17942453 | 0.86 | GPR119 (0.51) | KDM4EPKMGPR119TGFBR1MEN1 | |
| SCHEMBL25572016 | 0.85 | TGFBR1 (0.52) | KDM4EPKMGPR119STSTHRB | |
| SCHEMBL1474954 | 0.83 | KDM4E (0.53) | KDM4EPKMGPR119STSTHRB | |
| SCHEMBL7872006 | 0.82 | KDM4E (0.58) | KDM4EPKMGPR119STSTHRB | |
| SCHEMBL4480416 | 0.82 | GPR119 (0.57) | KDM4EPKMGPR119STSTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-07-02 | — | — | US | disclosed |
| EP-1771429-A1 | NEW BENZOYL UREA DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | OPRM1, GRIN2C, GRIN3A | KDM4E 2328/4885PKM 2819/4885GPR119 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.